A margetuximab agreement for MacroGenics and EVERSANA
MacroGenics and EVERSANA announce approval-dependent agreement to support launch and commercialization of margetuximab
Latest
Merck snaps up OncoImmune for $425M
The acquisition nets Merck a pipeline of oncology programs as well as CD24Fc, OncoImmune's lead candidate for the treatment of COVID-19
UCLA Health, Regeneron Genetics Center initiate research collaboration
The partners will conduct whole-exome sequencing on 150,000 patients in a partnership they say will advance personalized medicine
